In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae

Robin Patel, Mark S. Rouse, Kerryl E. Piper, James M. Steckelberg

Research output: Contribution to journalArticle

57 Scopus citations

Abstract

We report the activity of the new oxazolidinone antimicrobial agent linezolid against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 20 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by ≤ 4 ug/ml of linezolid. All isolates of methicillin-resistant S. aureus were inhibited by ≤ 8 ug/ml of linezolid. All isolates of penicillin-resistant S. pneumoniae were inhibited by ≤ 2 ug/ml of linezolid. Linezolid inhibits strains of multidrug resistant Gram-positive cocci in vitro at concentrations ≤ 8 ug/ml. Copyright (C) 1999 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)119-122
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume34
Issue number2
DOIs
StatePublished - Jun 1 1999

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae'. Together they form a unique fingerprint.

  • Cite this